CALL - SPRINTER OPEN END - VERTEX PHARMACEUTICALS | Delayed Deutsche Boerse AG 18:40:34 06/06/2024 BST | ||
| 11.58 EUR | -1.95% |
|
| Current month | +30.55% | ||
| 1 month | +139.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 06/06/24 | 11.58 | -1.95% |
| 05/06/24 | 11.81 | +10.68% |
| 04/06/24 | 10.67 | +4.00% |
| 03/06/24 | 10.26 | +15.67% |
| 31/05/24 | 8.87 | +12.99% |
Delayed Quote Deutsche Boerse AG
Last update June 06, 2024 at 06:40 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VU8GFA |
| ISIN | DE000VU8GFA7 |
| Date issued | 13/06/2023 |
| Strike | 357.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.17 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.81 € |
|---|---|
| Lowest since issue | 0.36 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
485.5
USD
Average target price
463.5
USD
Spread / Average Target
-4.53%
- Stock Market
- Certificates
- Certificat